课题基金 / 基金详情

Administrative-Core-001

Administrative-Core-001
行政核心-001
批准号:
10707579
负责人:
Zachary Scott Morris
金额:
$7.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-06-01 至 2025-05-31
关键词:

项目摘要

项目成果

Zachary Scott Morris的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结(同CA250972)
英文摘要
PROJECT SUMMARY (same as CA250972) This Program Project grant will establish the fully integrated interdisciplinary programs of research and core facilities that are necessary to develop a fundamental understanding of the complex interplay between two rapidly emerging fields in cancer therapy: 1) targeted radionuclide therapy (TRT) and 2) immunotherapy. Our overarching objectives are to develop a detailed mechanistic understanding of the immunomodulatory capacity of TRT agents and to evaluate and compare the ability of these agents to elicit cooperative therapeutic interactions in combination with immunotherapies. To achieve this, we will employ a representative variety of TRT agents to deliver radiation in vivo using clinically relevant murine tumor models and companion canines that have spontaneously developed cancers. We will determine the precise dosimetry for each radionuclide-, TRT vector-, and tumor model. This will facilitate studies of dose-, dose-rate-, and dose-range-dependent effects on the host immune system, tumor infiltrating immune cells, cytokine expression in the tumor microenvironment, immune susceptibility of tumor cells, mechanisms of immune suppression, and the development of antigenspecific adaptive immunity. We will determine the functional consequences of these effects by testing the broad hypothesis that, by modulating tumor immune tolerance and functional immunogenicity at all tumor sites, TRT will increase response to certain cancer immunotherapies. We will test this in the following Program Projects: Project 1: Novel TRTs for Dosimetry-Guided Immunomodulation, Project 2: TRT to enhance tumor cell immune susceptibility and response to immune checkpoint inhibitors, Project 3: Combining TRT with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses, Project 4: TRT with tumor-specific vaccine to stimulate and expand T-cell activation. These highly integrated projects will not only benefit from the methods and findings generated in one another, but they also will directly benefit from the expertise and service of four essential Core Facilities: 1) Advanced imaging and dosimetry core (AIDC), 2) Radiopharmaceutical and radiochemistry core (RPRC), 3) Biostatistics and bioinformatics core (BBC), and 4) Administrative core. Complementing these are robust institutional facilities that will enable successful completion of our proposed studies. Our multidisciplinary team brings together the broad expertise needed to mobilize these resources in pursuit of our proposed objectives. These efforts will further benefit from robust institutional matching support, leadership of a strong Internal Advisory Committee, invaluable Industry collaborations, and expertise of an External Advisory Board. Because of the immediate and broad potential for clinical translation of our results, these studies portend an opportunity to improve the treatment of any oncology patient, regardless of cancer type, tumor location, burden of disease, or patient age.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
  • 批准号:
    10737774
  • 项目类别:
  • 资助金额:
    $7.45万
  • 财政年份:
    2020
  • 负责人:
    Zachary Scott Morris
  • 依托单位:
Administrative-Core-001
  • 批准号:
    10895779
  • 项目类别:
  • 资助金额:
    $7.45万
  • 财政年份:
    2020
  • 负责人:
    Zachary Scott Morris
  • 依托单位:
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
  • 批准号:
    10672926
  • 项目类别:
  • 资助金额:
    $38.43万
  • 财政年份:
    2020
  • 负责人:
    Zachary Scott Morris
  • 依托单位:
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
  • 批准号:
    10672912
  • 项目类别:
  • 资助金额:
    $245.27万
  • 财政年份:
    2020
  • 负责人:
    Zachary Scott Morris
  • 依托单位:
国内基金
海外基金
胆固醇羟化酶CH25H非酶活依赖性促进乙型肝炎病毒蛋白Core及Pre-core降解的分子机制研究
  • 批准号:
    82371765
  • 项目类别:
    面上项目
  • 资助金额:
    50万元
  • 批准年份:
    2023
  • 负责人:
    谭广云
  • 依托单位:
锕系元素5f-in-core的GTH赝势和基组的开发
  • 批准号:
    22303037
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    鲁俊波
  • 依托单位:
基于合成致死策略搭建Core-matched前药共组装体克服肿瘤耐药的机制研究
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    孙丙军
  • 依托单位:
鼠伤寒沙门氏菌LPS core经由CD209/SphK1促进树突状细胞迁移加重炎症性肠病的机制研究
  • 批准号:
    --
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2022
  • 负责人:
    叶成林
  • 依托单位: